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 CONCLUSIONS 
We suggest that the mentioned polymorphisms in GSTM1 and G6PD genes may act as genetic modifiers in SCA, which could be useful for 
the prediction of increased susceptibility to complications. Furthermore, our results reinforce the importance to study biochemical 
parameters for a better understanding of the clinical outcome of this disease. 
INTRODUCTION 
Sickle cell anemia (SCA) is an inherited blood 
disorder characterized by the presence of 
hemoglobin S (HbS). This disease is caused by a 
mutation in the beta-globin gene (HBB:c.20A>T) 
on 11p15.5. The easily ability of Hb S to 
polymerize in deoxygenated conditions gives rise 
to abnormal sickled red blood cells (Figure 1) 
(Rees et al, 2010). Vaso-occlusion and hemolytic 
anemia are the major features of this disease, 
however SCA patients present clinical and 
hematologic variability that cannot be only 
explained by the single mutation in the beta-
globin gene. Others genetic modifiers and 
environmental effects are important in the clinical 
phenotype (Steinberg & Sebastiani, 2012).  
METHODS 
• We studied the association between several hematological 
and biochemical parameters and some genetic variants in 26 
pediatric SCA patients (mean age of 8.6 years) followed-up in 
Hospital de Dona Estefânia, in Lisbon.  
• MPO and PlGF were determined by ELISA (R&D Systems Inc.). 
Amplification of DNA samples for the rs1050829 
characterization, in the glucose-6-phosphate dehydrogenase 
(G6PD) gene, was performed by PCR followed by restriction 
fragment length analysis. A multiplex PCR assay was used for 
simultaneous amplification of glutathione S-transferases mu 
(GSTM1) and theta (GSTT1). All statistical tests were 
performed with SPSS 24.0 software. 
• Association studies were performed using T test/ ANOVA 
parametric tests or Mann-Whitney/Kruskal-Wallis 
nonparametric tests, all performed with SPSS 24.0 software. 
Figure 1 - Normal and sickled red blood cells .  
(In http://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/home/ovc-20303267) 
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RESULTS  
The following significant associations were 
observed (Table I, II, III and IV; Figure 2, 3, 4 and 
5): 
• We observed higher levels of MPO (p<0.001) 
and PlGF (p=0.048) in SCA patients. 
• Moreover, in these patients we found 
associations between: 1) lower levels of 
total hemoglobin and the GSTM1 null 
genotype (p=0.044); 2) higher levels of HbS 
with the rs1050829_G genotype 
(hemizygous males) in the G6PD gene 
(p=0.026). 
Figure 2 - Box plot showing distribution of MPO concentration 
among SCA patients and controls. 
Figure3 - Box plot showing distribution of PlGF concentration 
among SCA patients and controls. 
Figure 4 - Box plot showing distribution of total haemoglobin 
among positive and null genotypes at GSTM1 gene. 
Table II - Association between PlGF concentration and the presence or 
absence of SCA 
PlGF (pg/mL)  
 Population N Mean 
Standard 
deviation 
  
 p-value* 
  
SCA patients 13 6,24 3,95 
0.048 
Controls 23 3,69 2,35 
* T test 
 
 
Table III - Association between total haemoglobin and  GSTM1  genotypes 
Total Hb (g/dL)  
 GSTM1 genotype N Mean 
Standard 
deviation 
  
 p-value* 
  
positive  17 8,89 1,34 
0.044 
null  3 7,17 0,42 
* T test 
Table I - Association between MPO concentration and the presence or 
absence of SCA 
MPO (ng/mL) 
Population N Median Minimum Maximum 
 
p-value* 
 
SCA patients 14 29,56 14,14 78,63 
<0.001 
Controls 34 13,00 3,10 152,60 
* Mann-Whitney test 
 
Figure 5 - Box plot showing distribution of HbS in  
rs1050829 genotypes at G6PD gene. 
 
 
Table IV - Association between HbS and  G6PD  genotypes 
HbS (%) 
G6PD genotype N Mean Standard deviation 
  
 p-value* 
  
A/AA 10 71,90 5,60 
0.026 AG 3 70,73 6,11 
G 5 81,32 6,90 
* ANOVA 
